Ustekinumab biosimilar candidate achieves ‘therapeutic equivalence’

AVT04, a biosimilar candidate to ustekinumab developed by Alvotech, met the primary endpoint in a confirmatory clinical study of patients with chronic plaque-type psoriasis, according to a company press.
The confirmatory trial — a randomized, double-blind, multicenter study — enrolled 581 patients throughout four centers in Europe and aimed to investigate the efficacy and safety profile of AVT04 compared with ustekinumab (Stelara, Janssen). The trial investigated the drug in patients with “moderate to severe chronic plaque-type psoriasis.”
“The progress of our

AVT04, a biosimilar candidate to ustekinumab developed by Alvotech, met the primary endpoint in a confirmatory clinical study of patients with chronic plaque-type psoriasis, according to a company press.
The confirmatory trial — a randomized, double-blind, multicenter study — enrolled 581 patients throughout four centers in Europe and aimed to investigate the efficacy and safety profile of AVT04 compared with ustekinumab (Stelara, Janssen). The trial investigated the drug in patients with “moderate to severe chronic plaque-type psoriasis.”
“The progress of our